Completed
Prednisone for Duchenne Muscular Dystrophy Treatment
What is being tested
prednisone
Drug
Who is being recruted
Muscular Diseases+14
+ Musculoskeletal Diseases
+ Congenital, Hereditary, and Neonatal Diseases and Abnormalities
From 5 to 15 Years
How is the trial designed
Treatment Study
Phase 3
Interventional
Study Start: April 1995
Summary
Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Study start date: April 1, 1995
Actual date on which the first participant was enrolled.PROTOCOL OUTLINE: This is a randomized, double-blind study. Patients are randomly assigned to prednisone or placebo. Therapy is administered daily for 12 weeks; prednisone is then tapered.
Principal SponsorNational Center for Research Resources (NCRR)
Last updated: June 24, 2005
Sourced from a government-validated database.Claim as a partner
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Design Details
20 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Conditions
Criteria
Male
Biological sex of participants that are eligible to enroll.From 5 to 15 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Muscular DiseasesMusculoskeletal DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesNervous System DiseasesNeuromuscular DiseasesPathologic ProcessesSigns and SymptomsPathological Conditions, Signs and SymptomsMuscular Disorders, AtrophicDisease AttributesGenetic Diseases, X-LinkedMental DisordersMuscular DystrophiesNeurologic ManifestationsMuscular Dystrophy, DuchenneGenetic Diseases, InbornRare Diseases
Criteria
PROTOCOL ENTRY CRITERIA: Ambulatory males with Duchenne muscular dystrophy No medical/psychiatric contraindication to protocol therapy No requirement for regular use of prescription medication
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has no location dataSave this study to your profile to know when the location data is available.
CompletedNo study centers